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ABSTRACT
Intranasal route is the best method for high absorption and direct delivery to the brain. The interests and importance, of this route, are that the 
systemic effects of drugs when administered through the nasal route, have expanded over recent decades and it used for therapeutic and recreational 
purposes. In comparison with the parenteral route of drug administration, intra-nasal administration of drugs offers an interesting alternative for 
achieving systemic therapeutic effects of drugs. The oral administration of the drug produces low drug bioavailability, and this can be minimized 
using this nasal route. Moreover, the advantage of this route is that it can bypass the first-pass metabolism. Therefore, it is important to understand 
the potential and limitations of various nasal drug delivery systems. The aim of this review article is to discuss the various pharmaceutical dosage 
forms that have the potential to be utilized for local or systemic drug administration. It is assumingly expected that this review will help to understand 
about this route and also to develop suitable intra-nasal formulations to achieve specific therapeutic objectives. The different types of nasal drug 
formulations that can be used are nasal drops, nasal sprays, nasal gels, nasal suspensions and emulsion, and nasal powders.
Keywords: Intranasal, First-pass metabolism, Mucoadhesion, Bioavailability.
INTRODUCTION
Nasal cavity is one of the best methods for delivering the drug because it has 
faster and higher drug absorption. By this method, we can avoid first-pass 
metabolism and also drug absorption from the nasal site is higher permission 
when compared to the gastrointestinal tract (GIT). Many drugs are gastro 
liable, so we can overcome that problem by intranasal system. Nasal therapy 
is also ancient therapy, and we can call it as “NASAYA KARMA” [1].
Drawback of the system is mucociliary clearance due to mucociliary clearance 
bioavailability is reduced and main advantage is it is of self-medication. By 
animal model, many nasal drug deliveries have been tested. Nowadays, nasal 




For systemic actions, many researches are going on, and the available 
pharmaceutical dosage forms such as gel, solution, and liposomes and 
this is designed for quick response to the drug which administered 
through nasal, for example, oxymetazoline [2]. In our system highly 
lipid soluble drugs can be easily distribute well [3]. Intranasal 
administration of a drug has advantages; it directly acts to brain 
without entering into systemic circulation. By nasal delivery process, 
many drugs were discovered, and human nasal is regulated by tight 
junctions especially paracellular pathway. Paracellular plays important 
role for nasal mucosa drug administering way [4].
TIGHT JUNCTIONAL FORMATIONS
Tight junctions are formed by internal membranes various proteins, tricellin, 
occluding, lipo-lysis stimulated lipoprotein receptor, and junctional adhesion 
molecule and these tight junctions are worked under cytokines (IL, TNF) 
interleukins, tuber necrotizing factor by transduction pathways [4].
ANATOMY AND PHYSIOLOGY OF NOSE
By anatomically respiratory system is divided into two types:








Air primarily enters by the nose through external nares and secondarily 
into pharynx finally to posterior nares [5]. The total surface area of the 
nose is 160cm2, and it has volume about 16–19 ml [6]. Warm, humid 
air enters into nose which also provides filtration of the inspired 
air and the unwanted particles get adhesive by the mucoadhesive 
process. Physiologically nose has (1) vestibular, (2) turbinate, and (3) 
olfactory [7] (Figs. 1 and 2).
Vestibular part is starting point of nose which is anterior and 
very narrow stiff hair inside the nostrils which protect from the 
environmental particles and is capable of filtering size about 10 μm as 
it has stratified squamous epithelium [8].
The turbinate is highly blood perfusion area comprises three 
regions superior, middle, and inferior (Fig. 1) and turbinate is lined 
by pseudostriated columnar epithelium, and it is made by mucus-
secreting ciliated and non-movable microvillus which is highly 
responsible for increasing surface area due to non-movable response. 
The drug absorption is moderate. Ciliates are covered with motile 
cilia, and they are responsible for mucus transport of a drug that binds 
with mucociliary area as they could be expelled out and thus limited 
absorption only could occur [9-11]. The turbinate part consists of the 
following parts (a) vestibule, (b) atrium, (c1) inferior turbinate, (c2) 
middle turbinate, (c3) posterior turbinate, (d) olfactory bulb, and (e) 
nasopharynx [12].
Moreover, finally olfactory region and it’s important for transporting the 
drug to brain and cerebrospinal fluid it comprises 8% of the total surface 
area it is made by non-ciliated, pseudo striated columnar epithelium 
and a mucus layer is present which traps unwanted particle and mucus 
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secretion consists of salts, water, protein, albumin, immunoglobulins, 
and lysosomes [13]. pH of nasal secretions is about 5.9-6.5 [6,14].
Cells of nasal epithelium with covering mucus layer (a) ciliated cell, 
(b) non-ciliated cell, (c) corbel cell, (d) mucous gel layer, (e) sol layer, 
(f) basal layer, and (g) basement membrane [12].
DRUG FORMULATION CONSIDERATIONS
Nose has a higher surface area, which is potentially used drug delivery. 
The pharmaceutical development has a higher task for therapeutic 
objectives which is used for
• Local
• Systemic
• Single-repetitive dose loading
• By knowing the above status, it will be better for development of 
nasal delivery system is appropriate [15-17].
By knowing the factors that can affect drug absorption, disposition 
it can easy for making the novel, various pathological conditions and 
anatomical and physiological are also considered and in UK various 
nasal formations given in Table 1 [14].
ENHANCEMENT OF DRUG
Permission enhancer is added to the formulation which highly water-
soluble [27]. The exact mechanism of absorption and permission is not 
known and the permission enhancer will induce the epithelial barrier 
modifications so that the drug entry becomes easy [26]. Above the given 
Table 2, different type of permission enhancer absorption is listed with 
the mechanism.
NASAL DRUG DELIVERY ROUTE ADVANTAGES AND LIMITATIONS
1. While comparing other routes such as parental, oral nasal has high 
potential, it directly delivers the drug to brain (through olfactory 
nerve), so the nasal route is much attractive when compared to 
other [30]. Brain is a delicate and highly perfused organ it has a lot 
of functions (sensory and collection processing and integrity finally 
motor actions). It is protected from the environmental factors, tight 
junctions surrounding the brain is called blood–brain barrier (BBB). 
It has a great transendothelial resistance which also blocks drug 
transport the delivery to brain by nose has many drug transport 
system such as (1) paracellular and (2) transcellular and/or neuronal 
pathway [31].
2. The presence of olfactory pathway it efficiently bypasses the 
BBB [32]. Nasal route is better alternative route for drug absorption 
and also in patient with problems such as GIT infections and GI 
route (or) parental route is inconvenient Example: Patient with 
Zollinger-Ellison syndrome, vomiting patient unable to swallow 
(achalasia), difficulties in children and old aged persons [33]. 
The important limitation of the nasal route is not applicable for 
all drugs. To increase the drug half-life, we must know about 
the physiochemical properties such as acid base disassociation 
constant (pk), partition coefficient, molecular weight, and drug 
solubility [34].
3. Many drugs formulations are solution type. They are very difficult to 
absorb due to polar and low solubility as these cause poor membrane 
permeability, instant clearance, and enzymatic degradation within 
nasal canal [6].
4. Drug or fillers which cause the local irritation to the nasal mucosa [35].
5. Formulation factors also have a great impact and type of formulation 
such as solid, liquid, gel, powder, and pH also included [36].
6. Physical conditions of the nose like nasal atrophic rhinitis which 
can reduce the nasal drug absorption and may also physiological 
condition such as blood flow, mucociliary clearance also plays an 
important role for reducing the nasal drug absorption [33,37].
7. Presence of nasal mucous which also takes time for drug absorption 
and also reduces the contact time [38]. To overcome from the 
mucosa clearance by adding the mucoadhesive polymers in it (or) 
encapsulate with formulations so that bioavailability could be 
increased [39]. The drug absorption is distributed by major barriers 
is mucociliary and conditions like coryza, hay fever can change the 
mucociliary clearance, and some drugs may bind with mucins and 
decrease bioavailability of a drug [40-42].
MECHANISM OF ACTION THROUGH NASAL ROUTE
Mucous is the first step drug which has to pass through mucous layer 
tiny particles which may enter quickly and easily but larger particles 
have difficulties to enter [43]. Mucin is a protein substance present in 
mucous which has the potency to bind with drugs, and it alters the 
permeation process a structural modification of the mucus layer exists, 
so the result physiological changes occur [44]. The given drug that 




However, the paracellular and transcellular are major route [45].
Paracellular
It refers to the transfer of substances across an epithelium by passing 
through the intracellular spaces between the cells [46]. There is a direct 
correlation of a drug particle size and drug absorption because higher 
molecular weight does not cross well just bioavailability of the drug 
decreases [43].
Fig. 1: Taken from Google
Fig. 2:  Physiological diagram nose
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Transcellular
It is achieved with passive diffusion or transport mechanism [46]. 
Moreover, it also called lipoidal route it highly depends on lipophilicity of 
the drug, drug cross the membrane by active process using carrier [45].
Transcytosis
Drugs and macromolecules which are transported across the interior of 
the cell it forms a vesicle and transported to other side [46].
NASAL DRUG DIFFERENT TYPES OF FORMULATIONS
Nasal drops and sprays
Nasal drops by squeezing the bottle the nasal drops are used for local 
areas for local areas and also for mucociliary dysfunction [36,47]. Nasal 
delivery is easiest and simplest method for administration and also for 
formulations, and the major drawback of the system is contamination 
may occur during using periods and the exact and accurate amount of 
the drug administering also difficult [48]. The delivery is as follows:




Advantages of nasal spray are more accurate than nasal drops 
measured dose can expel out [36]. Nasal spray shown a consistent dose 
of reproducible plume geometry the droplet size and dose accuracy 
can be depended on formulation properties such as surface tension, 
viscosity, and thixotropy [49-52]. The design of the pump and orifice 
size can affect the nasal disposition sprays [17,48].
Nasal gel
By its characteristics, it is soft semisolid in nature and the semisolid 
characteristics can be two dynamic mechanical properties (i) elastic 
module G and (ii) viscous module G [34]. The flow properties of the 
nasal gel depends on vicious concentration and type of polymer 
for good results of biopharmaceutics bio-adhesive polymers 
plays a high role and these results a good improvement of patient 
complains [53,54]. A long time contact of a drug at the absorption site 
can increase the bioavailability because of slowing the mucociliary 
movement [55]. The mechanism of the mucoadhesive was explained 
by various theories, but the mechanism is generally based on two keys 
(i) contact and (ii) consolidation a long contact of polymer can diffuse 
with mucus [48]. Various non-harmful and biologically degradable 
polymers are discovered for mucoadhesive system Example-
Polyvinyl alcohol [56]. Mucoadhesive gels for nasal administration 
have been studied for different antibiotics such as ciprofloxacin [30], 
mometasone [57], carvedilol [58], and vaccines and proteins [59,60]. 
Some of the gels behave pseudoplasticity and their flow properties 
cannot be used for nasal delivery for this purpose gelation is used 
for overcome form that problem [61]. In polymeric formulations, the 
drug has to be solution form but after reaching into the body it should 
converted into gelation to the form of gel in a body depends on temp., 
pH, and ions in a body [62].
Table 1: Current formulations of nasal drug delivery system [14]
Indication Active pharmaceutical ingredient Formulation




Analgesic 1. Fentanyl citrate
2. Diamorphine HCL
Powder and diluents for reconstituent aqueous 
spray nasal spray sol
Endometriosis Nafarelin acetate Nasal spray sol
























Prostatic carcinoma Buserelin acetate Nasal spray
Nasal solution
Nasal congestion Levomenthol Nasal ointment




Nicotine withdrawal symptoms Nicotine Nasal spray solution
Nocturia with multiple sclerosis, sensitive cranial 
diabetes insipidus
Desmopressin acetate Nasal spray solution 
Vaccination Flu-vaccination Nasal spray suspension
Table 2: Nasal drug absorption enhancers
Class of compound Example Possible action References
Fatty acid Lysophosphotidyl choline Membrane disruption [18]
Surfactants SLS, saponin, polyoxyethylene Membrane disruption [19-22]
Bile salts Sodium glycolate, sodium deoxycholate, sodium 
taurodihydrofusidate
Enzyme inhibition, open tight junctions, 
mucolytic activity
[23-25]
Bio-adhesive material Carbopol, starch microsphere, chitosan Reduce nasal clearance, open tight junctions [26]
Enzyme inhibition Amastatia Enzyme inhibition [27]
Cyclodextrins derivatives Open tight junctions, membrane disruption [28,29]
SLS: Sodium laryl sulfate
36
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Nasal suspension and emulsion
Nasal suspension formulations are rare nowadays and the relativity 
of marked aqueous eye drops is preparing example - sodium 
carboxymethylcellulose and loteprednol etabonate [63]. The 
preparation of nasal suspension of insulin was studied by Ando 
et al. 1998 [64]. The absorption enhancers were used for nasal 
suspension such as soybean steryl glycoside and sterol mixture and 
their pharmacological actions about 6.7% and 11.3% have been 
achieved [65-68]. For nasal formulations, emulsions are better chosen 
over suspensions because emulsions will enhance the rate and extend 
of a drug of poorly soluble drugs so that low solubility drugs have 
been encapsulated or formulated with emulsions for drug solubility 
example-diazepam [69]. Nasal-suspensions ranging from 1 to 500 nm 
for brain targeting and it crosses the BBB and researches going on 
nasal-emulsions [70-72].
Nasal powders
Nasal powder dosage forms are simply formulated by active 
pharmaceutical ingredients with fillers [73,74]. There are two types 
of drying spray drying and freeze drying [75-77]. The insulin is mixed 
with water-insoluble derivatives such as cellulose and Carbopol 934p 
and that was administered nasal way once the drug took by water it 
swells and gives the pharmacological action and glucose level got 
reduced by one-third using IV-insulin dose [78]. Bioadhesive polymers 
of nasal delivery were formulated by dry powders and nasal delivery of 
proteins and peptides it was first established by Nagai and Thogersen 
1984 [79]. Beclomethasone dipropionate was coated with bioadhesive 
molecule and hydroxylpropyl used for carrier and it enhances the nasal 
resident time compared with nasal solution [80]. Indeed of highest 
bioavailability of the insulin was markedly decreased for the repeated 
administration of powder formulation [81]. The delivery drug has not 
been cleared from the nasal cavity because of physical barrier. Therefore 
it inhibits the drug penetration of inorganic substance such as calcium 
phosphate to enhance the drug absorption. This was demonstrated in 
rats for nasal absorption retardation at the site of administration which 
was proposed [74].
CONCLUSION
Nasal drug delivery system is one of the best potential and versatile 
routes for past many decades. It has a unique characteristic of drug 
release. It has bypassed the first-pass metabolism and also the drug has 
been directly delivered to brain so it has high potential of bioavailability. 
Various pharmaceutical dosage forms related to nasal utilized for the 
local or systemic drug has been discussed in this article intuitively, 
this review article will help for further new developed intranasal 
formulations to achieve the proper bioavailability practical and 
technical issue were discudded in this article a problem or difficulty to 
overcome for full potential to be realized.
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